Skip to main content

Hi Pierce and Alyssa,

I thoroughly enjoyed the discussion we had about antibiotic discovery especially due to the ever so becoming importance with the emergence of antimicrobial resistance! From some quick research, I learned that bacteria develop resistance through a few main mechanisms: enzymatic inactivation, overexpression of efflux pumps, decreased permeability and modifications that change biding of the antibiotics (1). To address your comment Alyssa, it seems like the use of non-essential target inhibitors as antibiotics adjuvants that increase susceptibility of bacteria to antibiotics are becoming commonly used. While these methods could be considered a form of combination therapy, I too am wondering if this might be the most feasible way to fight antimicrobial resistance. Does anyone know if focusing on developing drugs that increase permeability and stop the efflux of antibiotics from bacteria would be "easier" than looking at new antibiotics through inferiority trials? My thoughts are that developing these drugs could target similar traits of bacteria and be more widely used, but I would love to hear the thoughts of others!


(1) Annunziato, G. (2019). Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: A review. International journal of molecular sciences, 20(23), 5844.

Cassie Brand

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.